When it comes to combating cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex microenvironment, creating significant unmet needs which must be addressed. It’s why we selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers.

Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition.

Verastem’s first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).

Our Headquarters

Verastem Oncology
117 Kendrick Street Suite 500
Needham, MA 02494

Contact Us